Clinical Trial Update: Evaluation of D-Fi for the Treatment of Wounds Due to DEB [Phase 3]

View source ↗

Summary

This entry reports that Castle Creek Biosciences' Phase 3 trial evaluating D-Fi for treating wounds in Dystrophic Epidermolysis Bullosa is active but not recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dystrophic Epidermolysis Bullosa

Drugs mentioned

• D-Fi

Snippet

Sponsor: Castle Creek Biosciences, LLC. | Conditions: Dystrophic Epidermolysis Bullosa | Phase 3 | Status: ACTIVE_NOT_RECRUITING